Manufacturers

Sun Pharmaceutical Industries Ltd

Salt Composition

Pioglitazone (15mg) + Glimepiride (2mg)

Medicine Type

drugs

Introduction

In Treatment of Type 2 diabetes mellitus Pioglar-G Tablet is a medicine that helps to control high blood glucose (sugar) levels. It helps get rid of extra glucose from your body through urine. It also improves the body’s response to the hormone insulin, which is responsible for regulating blood glucose (sugar) levels in our body. The insulin helps to lower your blood glucose levels and prevents them from rising after taking meals. You should keep taking it for as long as it is prescribed.u003cbr>Lowering blood glucose levels is an essential part of managing diabetes. If you can control the level you will reduce the risk of getting any of the serious complications of diabetes such as kidney damage, eye damage, nerve problems, and loss of limbs. Taking this medicine regularly along with proper diet and exercise will help you live a normal, healthy life.

Benefits

Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Pioglar-G Tablet is to be taken with food.

Description

Pioglar-G Tablet is a combination medicine that helps control blood sugar levels. This medicine is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. Adequate sugar control lessens your risk of heart attack or stroke also.Pioglar-G Tablet should be taken in the dose and duration as advised by your doctor. It must be taken with food to avoid stomach upset. If you miss a dose, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose. Overdose may lead to low blood sugar (hypoglycemia).Some people may develop edema (swelling), cold symptoms, headache, urinary tract infection, diarrhea, nausea, leg pain, reduced blood cell count, infection, and accidental injury. However, these are temporary and usually subside on their own. If these do not resolve or bother you, please consult your doctor.Before taking this medicine, inform your doctor if you have any kidney, liver or heart problems. Pregnant or breastfeeding women should also consult their doctor before taking it. Your doctor will check your kidney function tests before starting treatment with it. Avoid excessive alcohol intake while taking it as this may increase the risk of developing some side effects.

How To Use

Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Pioglar-G Tablet is to be taken with food.

Safety Advise

- Alcohol : UNSAFE

It is unsafe to consume alcohol with Pioglar-G Tablet. | - Pregnancy : CONSULT YOUR DOCTOR

Pioglar-G Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor. | - Breast feeding : SAFE IF PRESCRIBED

Pioglar-G Tablet is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.Monitoring of the breastfed infant's blood glucose is advisable during maternal therapy with Pioglar-G Tablet | - Driving : CAUTION

Your ability to drive may be affected if your blood sugar is too low or too high. Do not drive if these symptoms occur. | - Kidney : CAUTION

Pioglar-G Tablet should be used with caution in patients with kidney disease. Dose adjustment of Pioglar-G Tablet may be needed. Please consult your doctor.Use of Pioglar-G Tablet is not recommended in patients with severe kidney disease. These patients can experience very low blood sugar levels which may become normal after a long time. | - Liver : CAUTION

Pioglar-G Tablet should be used with caution in patients with liver disease. Dose adjustment of Pioglar-G Tablet may be needed. Please consult your doctor.Use of Pioglar-G Tablet is not recommended in patients with severe liver disease. These patients can experience very low blood sugar levels which may become normal after a long time.

Packaging Detail

strip of 10 tablets

Package

Strip

Qty

10

Product Form

Tablet

Prescription Required

Prescription Required

Fact Box

Habit Forming :: No|Therapeutic Class :: ANTI DIABETIC

Primary Use

Treatment of Type 2 diabetes mellitus

Storage

Store below 30°C

Use Of

Treatment of Type 2 diabetes mellitus

Common Side Effect

Edema (swelling) | Cold symptoms | Headache | Urinary tract infection | Diarrhea | Nausea | Leg pain | Decreased blood cells (red cells, white cells, and platelets) | Infection | Accidental injury

Alcoholinteraction

UNSAFE

Pregnancyinteraction

CONSULT YOUR DOCTOR

Lactationinteraction

SAFE IF PRESCRIBED

Drivinginteraction

CAUTION

Kidneyinteraction

CAUTION

Liverinteraction

CAUTION

Manufacturer Address

Plot no 107/108,Namli block , Ranipool, East Sikkim 737135

How It Works

Pioglar-G Tablet is a combination of two antidiabetic medicines:.

Marketer Details

Sun Pharmaceutical Industries Ltd | Plot no 107/108,Namli block , Ranipool, East Sikkim 737135

Reference

Quinn CE, Hamilton PK, Lockhart CJ, et al. Thiazolidinediones: Effects on insulin resistance and the cardiovascular system. Br J Pharmacol. 2008;153(4):636-45. [Accessed 21 Jan. 2019] (online) Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2259217/ | Drugs.com. Pioglitazone+Glimepiride. [Accessed 08 Apr. 2019] (online) Available from: https://www.drugs.com/mtm/glimepiride-and-pioglitazone.html | Mayo Clinic. Pioglitazone and Glimepiride. [Accessed 08 Apr. 2019] (online) Available from: https://www.mayoclinic.org/drugs-supplements/pioglitazone-and-glimepiride-oral-route/proper-use/drg-20068956 | Pioglitazone. County Wicklow, Ireland: Takeda Ireland Limited. [Accessed 08 Apr. 2019] (online) Available from: https://www.ema.europa.eu/en/documents/product-information/tandemact-epar-product-information_en.pdf